Welcome!

News Feed Item

Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280946/Spinal-Muscular-Atrophy-SMA-Global-Clinical-Trials-Review-H2-2014.html

Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014" provides data on the Spinal Muscular Atrophy (SMA) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Muscular Atrophy (SMA). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinal Muscular Atrophy (SMA). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Spinal Muscular Atrophy (SMA) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Spinal Muscular Atrophy (SMA) 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials 29
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
Isis Pharmaceuticals, Inc. 32
Clinical Trial Overview of Isis Pharmaceuticals, Inc. 32
Trophos SA 33
Clinical Trial Overview of Trophos SA 33
Westat, Inc. 34
Clinical Trial Overview of Westat, Inc. 34
Repligen Corporation 35
Clinical Trial Overview of Repligen Corporation 35
PTC Therapeutics, Inc. 36
Clinical Trial Overview of PTC Therapeutics, Inc. 36
Natera, Inc. 37
Clinical Trial Overview of Natera, Inc. 37
Hill-Rom Holdings, Inc. 38
Clinical Trial Overview of Hill-Rom Holdings, Inc. 38
GlaxoSmithKline plc 39
Clinical Trial Overview of GlaxoSmithKline plc 39
F. Hoffmann-La Roche Ltd. 40
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 40
Clinical Trial Overview of Top Institutes / Government 41
University of Utah 41
Clinical Trial Overview of University of Utah 41
National Institute of Neurological Disorders and Stroke 42
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 42
Columbia University 43
Clinical Trial Overview of Columbia University 43
Assistance Publique - Hopitaux de Paris 44
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 44
Stanford University 45
Clinical Trial Overview of Stanford University 45
All India Institute of Medical Sciences 46
Clinical Trial Overview of All India Institute of Medical Sciences 46
Nagoya University 47
Clinical Trial Overview of Nagoya University 47
JASMITT Clinical Trial Office 48
Clinical Trial Overview of JASMITT Clinical Trial Office 48
National Taiwan University Hospital 49
Clinical Trial Overview of National Taiwan University Hospital 49
University Hospital Freiburg 50
Clinical Trial Overview of University Hospital Freiburg 50
Five Key Clinical Profiles 51
Appendix 77
Abbreviations 77
Definitions 77
Research Methodology 78
Secondary Research 78
About GlobalData 79
Contact Us 79
Disclaimer 79
Source 79

List of Tables

Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Muscular Atrophy (SMA) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Isis Pharmaceuticals, Inc., 2014* 32
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Trophos SA, 2014* 33
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Westat, Inc., 2014* 34
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Repligen Corporation, 2014* 35
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by PTC Therapeutics, Inc., 2014* 36
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Natera, Inc., 2014* 37
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hill-Rom Holdings, Inc., 2014* 38
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 39
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 40
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Utah, 2014* 41
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 42
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2014* 43
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 44
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 45
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by All India Institute of Medical Sciences, 2014* 46
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nagoya University, 2014* 47
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by JASMITT Clinical Trial Office, 2014* 48
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 49
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Freiburg, 2014* 50

List of Figures

Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Muscular Atrophy (SMA) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 78

To order this report: Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280946/Spinal-Muscular-Atrophy-SMA-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time t...
Sanjeev Sharma Joins November 11-13, 2018 @DevOpsSummit at @CloudEXPO New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
DXWorldEXPO LLC announced today that Kevin Jackson joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Kevin L. Jackson is a globally recognized cloud computing expert and Founder/Author of the award winning "Cloud Musings" blog. Mr. Jackson has also been recognized as a "Top 100 Cybersecurity Influencer and Brand" by Onalytica (2015), a Huffington Post "Top 100 Cloud Computing Experts on Twitter" (2013) and a "Top 50 C...
Charles Araujo is an industry analyst, internationally recognized authority on the Digital Enterprise and author of The Quantum Age of IT: Why Everything You Know About IT is About to Change. As Principal Analyst with Intellyx, he writes, speaks and advises organizations on how to navigate through this time of disruption. He is also the founder of The Institute for Digital Transformation and a sought after keynote speaker. He has been a regular contributor to both InformationWeek and CIO Insight...
When talking IoT we often focus on the devices, the sensors, the hardware itself. The new smart appliances, the new smart or self-driving cars (which are amalgamations of many ‘things'). When we are looking at the world of IoT, we should take a step back, look at the big picture. What value are these devices providing. IoT is not about the devices, its about the data consumed and generated. The devices are tools, mechanisms, conduits. This paper discusses the considerations when dealing with the...
Digital Transformation is much more than a buzzword. The radical shift to digital mechanisms for almost every process is evident across all industries and verticals. This is often especially true in financial services, where the legacy environment is many times unable to keep up with the rapidly shifting demands of the consumer. The constant pressure to provide complete, omnichannel delivery of customer-facing solutions to meet both regulatory and customer demands is putting enormous pressure on...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
SYS-CON Events announced today that IoT Global Network has been named “Media Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. The IoT Global Network is a platform where you can connect with industry experts and network across the IoT community to build the successful IoT business of the future.
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
CloudEXPO New York 2018, colocated with DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
Enterprises are universally struggling to understand where the new tools and methodologies of DevOps fit into their organizations, and are universally making the same mistakes. These mistakes are not unavoidable, and in fact, avoiding them gifts an organization with sustained competitive advantage, just like it did for Japanese Manufacturing Post WWII.
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
DXWorldEXPO | CloudEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.